CAJ | 학술논문

目的：探讨手术前后不同部位和不同病理类型的脑肿瘤患者抑郁状况的差异及临床特点。方法采用汉密尔顿抑郁量表（Hamilton Depression Rating Scale，HRSD）在手术前后分别对140例脑肿瘤患者进行评估，分析比较手术前后不同部位和不同病理类型的脑肿瘤患者抑郁分布状况和临床特征。结果140例脑肿瘤患者术前抑郁病例数及患病率为50例（35.7％），评分为15.36±6.52；术后抑郁病例数及患病率为9例（6.4％），评分为9.71±5.55。手术前后所有受试者的抑郁评分有显著统计学差异，术后抑郁评分较术前明显降低（P＜0.05）；术后抑郁患病率较术前显著下降（χ2=36.10，P＜0.05）；良、恶性脑肿瘤术后抑郁评分较术前有明显改善（P＜0.05、P＜0.05），左、右及双侧病变组术后抑郁评分较术前均显著下降（P均＜0.05）。结论脑肿瘤患围手术期即存在着不同程度的抑郁，抑郁可能与脑肿瘤的病理性质和部位有关。
목적：탐토수술전후불동부위화불동병리류형적뇌종류환자억욱상황적차이급림상특점。방법채용한밀이돈억욱량표（Hamilton Depression Rating Scale，HRSD）재수술전후분별대140례뇌종류환자진행평고，분석비교수술전후불동부위화불동병리류형적뇌종류환자억욱분포상황화림상특정。결과140례뇌종류환자술전억욱병례수급환병솔위50례（35.7％），평분위15.36±6.52；술후억욱병례수급환병솔위9례（6.4％），평분위9.71±5.55。수술전후소유수시자적억욱평분유현저통계학차이，술후억욱평분교술전명현강저（P＜0.05）；술후억욱환병솔교술전현저하강（χ2=36.10，P＜0.05）；량、악성뇌종류술후억욱평분교술전유명현개선（P＜0.05、P＜0.05），좌、우급쌍측병변조술후억욱평분교술전균현저하강（P균＜0.05）。결론뇌종류환위수술기즉존재착불동정도적억욱，억욱가능여뇌종류적병이성질화부위유관。
Objective To investigate the clinical features and incidence of depression in patients with different lo-cations and pathological types of brain tumors. Methods Hamilton Depression Scale (HRSD) was used to assess the de-pression in 140 patients with brain tumor before and after operation. Results The preoperative mean depression rating score was 15.36 ± 6.52 and the prevalence rate of depression was 50 cases (35.7%) in 140 patients with brain tumor. The postoperative mean score of depression was 9.71 ± 5.55 and the prevalence rate of depression was 9 cases (6.4%) in 140 patients with brain tumor. The postoperative depression score and the prevalence rate was significantly decreased after op-eration (P<0.05)(χ2=36.10,P<0.05). The postoperative depression score in either benign or malignant brain tumors was significantly lower after than before operation(all P<0.05)The postoperative depression score in either the left or right or bilateral brain lesions were significantly decreased after than before operation(all P<0.05).Conclusion Pa-tients with brain tumors have different degrees of depression in perioperative. Depression may be associated with brain tu-mour pathological types and lesion sites in patients with brain tumors.